Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Oct 8;74(14):1741-1755.
doi: 10.1016/j.jacc.2019.07.074.

Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain

Raymond Y Kwong  1 , Yin Ge  2 , Kevin Steel  3 , Scott Bingham  4 , Shuaib Abdullah  5 , Kana Fujikura  2 , Wei Wang  6 , Ankur Pandya  7 , Yi-Yun Chen  2 , J Ronald Mikolich  8 , Sebastian Boland  8 , Andrew E Arai  9 , W Patricia Bandettini  9 , Sujata M Shanbhag  9 , Amit R Patel  10 , Akhil Narang  10 , Afshin Farzaneh-Far  11 , Benjamin Romer  11 , John F Heitner  12 , Jean Y Ho  12 , Jaspal Singh  12 , Chetan Shenoy  13 , Andrew Hughes  13 , Steve W Leung  14 , Meera Marji  14 , Jorge A Gonzalez  15 , Sandeep Mehta  15 , Dipan J Shah  16 , Dany Debs  16 , Subha V Raman  17 , Avirup Guha  17 , Victor A Ferrari  18 , Jeanette Schulz-Menger  19 , Rory Hachamovitch  20 , Matthias Stuber  21 , Orlando P Simonetti  17
Affiliations
Clinical Trial

Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain

Raymond Y Kwong et al. J Am Coll Cardiol. .

Abstract

Background: Stress cardiac magnetic resonance imaging (CMR) has demonstrated excellent diagnostic and prognostic value in single-center studies.

Objectives: This study sought to investigate the prognostic value of stress CMR and downstream costs from subsequent cardiac testing in a retrospective multicenter study in the United States.

Methods: In this retrospective study, consecutive patients from 13 centers across 11 states who presented with a chest pain syndrome and were referred for stress CMR were followed for a target period of 4 years. The authors associated CMR findings with a primary outcome of cardiovascular death or nonfatal myocardial infarction using competing risk-adjusted regression models and downstream costs of ischemia testing using published Medicare national payment rates.

Results: In this study, 2,349 patients (63 ± 11 years of age, 47% female) were followed for a median of 5.4 years. Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 patients (67%), experienced low annualized rates of primary outcome (<1%) and coronary revascularization (1% to 3%), across all years of study follow-up. In contrast, patients with ischemia+/LGE+ experienced a >4-fold higher annual primary outcome rate and a >10-fold higher rate of coronary revascularization during the first year after CMR. Patients with ischemia and LGE both negative had low average annual cost spent on ischemia testing across all years of follow-up, and this pattern was similar across the 4 practice environments of the participating centers.

Conclusions: In a multicenter U.S. cohort with stable chest pain syndromes, stress CMR performed at experienced centers offers effective cardiac prognostication. Patients without CMR ischemia or LGE experienced a low incidence of cardiac events, little need for coronary revascularization, and low spending on subsequent ischemia testing. (Stress CMR Perfusion Imaging in the United States [SPINS]: A Society for Cardiovascular Resonance Registry Study; NCT03192891).

Keywords: cost of care; prognosis; stress cardiac magnetic resonance imaging.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. Primary and Secondary Outcome Event Rates
Annualized rates of primary and secondary outcomes, stratified by presence and/or absence of ischemia and left gadolinium enhancement (LGE) (left) and extent of ischemia (right).
FIGURE 2
FIGURE 2. Primary Outcome Over Years of Follow-Up
Occurrence of primary outcome across different years of study follow-up, stratified by presence and/or absence of ischemia and left gadolinium enhancement (LGE).
FIGURE 3
FIGURE 3. Need for Coronary Revascularization
Occurrence of coronary revascularization across different years of study follow-up, stratified by presence and/or absence of ischemia and left gadolinium enhancement (LGE).
FIGURE 4
FIGURE 4. Invasive XCA and Revascularization at 90 Days
Referral to invasive coronary angiography (XCA) at 90-day post-stress cardiac magnetic resonance imaging with corresponding proportion of patients undergoing revascularization (Revasc), stratified by presence and/or absence of ischemia and left gadolinium enhancement (LGE) (left) and extent of ischemia (right).
FIGURE 5
FIGURE 5. Costs of Ischemia Testing
Costs of downstream cardiac tests incurred during follow-up, stratified by stress cardiac magnetic resonance imaging (CMR) findings with breakdown by modality. Costs are in U.S. dollars spent per patient. CTA = computed tomography angiography; LGE = late gadolinium enhancement.
FIGURE 6
FIGURE 6. Invasive XCA at 90 Days, Stratified by Practice Types
Referral to invasive XCA at 90-day post stress CMR, stratified by presence and/or absence of ischemia and LGE, according to practice environment. Abbreviations as in Figures 1, 4, and 5.
CENTRAL ILLUSTRATION
CENTRAL ILLUSTRATION. Stress Cardiac Magnetic Resonance Imaging Registry for Prognosis and Costs in the United States
Cumulative incidence functions for primary and secondary outcomes derived from a Fine and Gray competing risk model accounting for noncardiovascular death as a competing risk event. The top panels were stratified by presence and/or absence of ischemia and late gadolinium enhancement, and the bottom panels were stratified by the extent of ischemia.
See this image and copyright information in PMC

Comment in

References

    1. Schwitter J, Wacker CM, Wilke N, et al. for the MR-IMPACT Investigators. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. Eur Heart J 2013;34:775–81. - PubMed
    1. Schwitter J, Wacker CM, Wilke N, et al. for the MR-IMPACT Investigators. Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: the secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial). J Cardiovasc Magn Reson 2012;14:61. - PMC - PubMed
    1. Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 2008;29:480–9. - PubMed
    1. Watkins S, McGeoch R, Lyne J, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009;120:2207–13. - PubMed
    1. Bodi V, Sanchis J, Lopez-Lereu MP, et al. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol 2007;50:1174–9. - PubMed

Publication types

Associated data